On statin drugs on the inhibition of cardiac hypertrophy.docVIP

 PAGE \* MERGEFORMAT 14 On statin drugs on the inhibition of cardiac hypertrophy [Keywords:] HMG coenzyme A reductase acid mono-inhibitors, cardiac hypertrophy, review Left ventricular hypertrophy as an independent decision of various cardiovascular diseases the main determinant of mortality (1), it cardiomyocyte hypertrophy and interstitial components of change (characterized by myocardial remodeling. Cardiac hypertrophy is the role of the extracellular stimuli cells and the process through a series of signal transduction induced intracellular gene activation and inactivation, which led to the result of changes in cell phenotype. Thus cardiac hypertrophy can choose from several aspects. statins is HMG acid mono coenzyme A (3 hydroxy 3 methylglutaryl coenzyme A, HMG CoA reductase inhibitors, by blocking the enzyme that can reduce cholesterol synthesis, increased cholesterol removal, to the role of lipid. In addition to lipid-lowering statin drugs other than functions, such as anti-inflammatory, antioxidant, protecting endothelial function. So statins can inhibit cardiac hypertrophy in many areas of the place. 1 on the inhibition of cell signal transduction Statin inhibition of cell hypertrophy by inhibiting the mevalonate pathway, interference with small G proteins (small G protein, small molecular G proteins, also known as the GTPase, the GTP enzyme activity achieved. GTP enzymes including Ras, Rho (including Rho, Rac, cdc42 and other family members, etc.. in the onset of its synthesis and isoprenylation process to go through that GTP enzyme carboxyl-terminal cysteine with thiol metabolites of mevalonate pyrophosphate Law does lipid (farnesyl pyrophosphate, FPP, geranyl pyrophosphate-based beef cattle Dragon Dragon geranyl acetate (geranylgeranyl pyrophosphate, GGPP isoprenoids such as the formation of covalent disulfide bond, which is such a protein required for post-translational maturation The (2). normally only after isoprenylation of GTP enzym